How effective is cimepilimab?

Cemiplimab (Cemiplimab) is a programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC) and non-small cell lung cancer (NSCLC). Its therapeutic effects include understanding through the following methods:

1. Cutaneous squamous cell carcinoma:Cimepilimab can effectively treat patients with cutaneous squamous cell carcinoma. In a major study involving a total of 193 patients, about 39% of patients with metastatic disease who received cimepilimab every 3 weeks saw their cancer shrink over about a year. Among patients with locally advanced disease who received cimepilimab every two weeks for 2 years, 44% showed their cancer shrank.

2. Basal cell carcinoma:Cimepilimab has shown benefit in the treatment of patients with locally advanced and metastatic basal cell carcinoma. In a study involving patients who took cimepilimab for one year, 32% (27 of 84) of patients with locally advanced disease and 29% (10 of 35) of patients with metastatic disease saw their cancer shrink. In this study, cimipilimab was not compared to another treatment.

3. Non-small cell lung cancer: In a study involving710 patients with advanced or metastatic EGFR/ALK/ROS1-negative non-small cell lung cancer, these patients had high levels of PD-L1 (in more than 5 0% of tumor cells), patients treated with cimepilimab lived longer (about22 months on average) than those treated with platinum-based chemotherapy (about14 months). Patients treated with cimepilimab lived an average of 6.2 months, while patients treated with chemotherapy lived an average of 5.6 months.

Another study involving 466 patients with advanced or metastatic EGFR/ALK/ROS1-negative non-small cell lung cancer found that cimepilimab, a platinum-based chemotherapy drug, increased survival time in patients whose tumors produced PD-L1 in at least 1% of cells in their tumors. Among 327 patients who had at least 1% of their tumor cells harboring PD-L1, those who received cimipilimab plus platinum-based chemotherapy lived an average of 22 months, compared with an average of 13 months for those who received platinum-based chemotherapy alone. Additionally, patients who received cimepilimab plus chemotherapy lived about nine months without their disease worsening, compared with six months for those who received chemotherapy alone.

Additionally, cimepilimab has been studied in cervical cancer. In one item forIn the main study of 608 patients with recurrent or metastatic cervical cancer who had previously received platinum-based chemotherapy, patients who received cimipilimab lived about 12 months, while those who received chemotherapy lived for 8.5 months. On average, patients who received cimepilimab lived without worsening for 2.8 months, while those who received chemotherapy lived for 2.9 months.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo